Approval of Adcetris provides a new treatment option for patients with relapsed or refractory large b-cell lymphoma who are ...
Corbus Pharmaceuticals has posted the first Western clinical data on its would-be rival to Pfizer’s Padcev. The overall ...
Pfizer's Super Bowl ad received mixed reactions on social media, but many criticized the pharma giant for saying it will ...
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental ...
Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (OTC:ALPMF) (OTC:ALPMY) released additional follow-up results from the Phase ...
After an apparent accidental early release, Pfizer has revealed phase 1 data showing its investigational candidate, alongside ...
Leaked data showed that Pfizer’s mevrometostat has strong therapeutic potential in metastatic castration-resistant prostate ...
Pfizer (PFE) and Astellas Pharma announced additional follow-up results from the Phase 3 EV-302 clinical trial evaluating the efficacy and ...
Pfizer’s Adcetris combination regimen gets US FDA approval to treat relapsed/refractory diffuse large B-cell lymphoma: New York Friday, February 14, 2025, 11:00 Hrs [IST] Pfizer ...
Pfizer (PFE) announced that the U.S. FDA has approved the supplemental Biologics License Application for ADCETRIS in combination with ...
Pfizer's Phase 3 BREAKWATER trial showed Braftovi combo significantly improved PFS and OS in colorectal cancer with BRAF ...
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback